Valuation: Atossa Therapeutics, Inc.

Market Cap 20.32M 17.61M 16.49M 15.04M 28.31M 1.94B 28.79M 193M 75.75M 970M 76.31M 74.64M 3.24B P/E 2026 *
-0.55x
P/E 2027 * -0.69x
Enterprise Value 20.32M 17.61M 16.49M 15.04M 28.31M 1.94B 28.79M 193M 75.75M 970M 76.31M 74.64M 3.24B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-0.21%
1 week-3.35%
Current month+11.59%
1 month-3.75%
3 months-55.23%
6 months-41.37%
Current year-73.90%
1 week 2.24
Extreme 2.24
2.45
1 month 2.05
Extreme 2.05
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
756
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap.
1/20/26 Free

Chief Executive Officer

1,281,674 0.9922%
1/20/26
Ensisheim Partners LLC
OtherCompany 0 0%
10/14/25 Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-3.35%-80.07%-84.01% 20.32M
-1.69%+0.71%+3.55%+14.41% 49.54B
+0.82%+4.56%+485.10%+587.68% 44.06B
-0.25%+9.46%+24.44%+75.63% 40.85B
-0.65%+2.55%+30.21%+9.97% 40.14B
-4.04%+8.72%+22.60%+48.00% 34.17B
-0.63%+1.80%+30.27%+125.25% 16.9B
+0.92%+5.04% - - 16.78B
-0.17%+0.14%+4.49%+21.02% 14B
+1.62%+9.38%+86.69%+31.47% 13.46B
Average -0.42%+6.49%+67.48%+92.16% 26.99B
Weighted average by Cap. -0.73%+6.51%+103.78%+136.56%

Financials

2026 *2027 *
Net sales - -
Net income -37.06M -32.12M -30.07M -27.43M -51.63M -3.53B -52.49M -353M -138M -1.77B -139M -136M -5.9B -39.36M -34.11M -31.93M -29.13M -54.83M -3.75B -55.75M -374M -147M -1.88B -148M -145M -6.27B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-08-12 $2.310 -2.12% 19,577
26-08-11 $2.360 -0.42% 56,704
26-08-10 $2.370 +0.42% 69,086
26-08-07 $2.360 -2.48% 78,020
26-08-06 $2.420 +1.26% 30,786
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.360USD
Average target price
18.67USD
Spread / Average Target
+690.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock